We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Database Provides First-Ever Map of Proteome Signature in Blood from Cancer Patients

By LabMedica International staff writers
Posted on 10 Jan 2023
Print article
Image: The yellow bar in this readout of protein GFAP indicates elevated expression in blood of patients with brain tumors (Photo courtesy of Human Protein Atlas)
Image: The yellow bar in this readout of protein GFAP indicates elevated expression in blood of patients with brain tumors (Photo courtesy of Human Protein Atlas)

Cancer prediction medicine has received a boost with the recent unveiling of a new cancer protein profile database compiled from AI and machine learning that enables identification of individual cancer types based on a drop of blood.

The new open-access Disease Blood Atlas produced by the Human Protein Atlas (Sweden) consortium provides a first-ever map of the proteome signature in blood from cancer patients. The Disease Blood Atlas highlights 1,463 proteins associated with 12 different types of cancer, and presents proteins that can be used to identify individual cancer types based on a drop of blood.

The Disease Blood Atlas was compiled from measurements of minute amounts of blood plasma collected from 1,400 cancer patients at the time of diagnosis and before treatment. The blood samples underwent a combination of statistical analysis of gene expression and machine-learning-based disease prediction. The release marks the 22nd version of the open-access Human Protein Atlas, a resource for profiling human proteins, which contains 12 sections each exploring the human proteins from different angles, including the new Disease Blood Atlas and the Protein 3-D Structure sections.

The release is accompanied by five million pages of updates in the Human Protein Atlas’ databases of tissues and cell lines. The Protein 3-D Structure section shows the 3-D structures for all human proteins using an AI-based prediction model (AlfaFold). In addition, a major update of the Tissue Atlas section provides detailed multiplex spatial profiling of proteins specific for human testis and kidney. More data is also provided on single cell analysis of tissues and organs, as well as data from an extensive catalogue of human cell lines.

“This is a novel pan-cancer strategy for exploring the proteome signature in blood from cancer patients,” said KTH Royal Institute of Technology Professor Mathias Uhlén who led the Human Protein Atlas consortium. “We believe that the new sections of the open access Human Protein Atlas with large amounts of novel data covering all human proteins provides new dimensions of valuable information for researchers interested in human biology and disease.”

Related Links:
Human Protein Atlas

New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
ELISA System
ABSOL HS DUO
New
Incubator
HettCube 120

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.